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Abstract
Glioblastoma multiforme (GBM) is a poor prognosis type of tumour due to its resistance to
chemo and radiotherapy. SOCS1 and SOCS3 have been associated with tumour progres-
sion and response to treatments in different kinds of cancers, including GBM. In this study,
cell lines of IDH-wildtype GBM from primary cultures were obtained, and the role of SOCS1
and SOCS3 in the radiotherapy response was analysed. Fifty-two brain aspirates from GBM
patients were processed, and six new cell lines of IDH-wildtype GBM were established.
These new cell lines were characterized according to the WHO classification of CNS
tumours. SOCS1 and SOCS3 expression levels were determined, at mRNA level by Q-
PCR, at protein level by immunocytochemistry, and Western blot analysis. The results
showed that SOCS1 and SOCS3 are overexpressed in GBM, as compared to a non-tumoral
brain RNA pool. SOCS1 and SOCS3 expression were reduced by siRNA, and it was found
that SOCS3 inhibition increases radioresistance in GBM cell lines, suggesting a key role of
SOCS3 in radioresistant acquisition. In addition, radioresistant clonal populations obtained
by selective pressure on these cell cultures also showed a significant decrease in SOCS3
expression, while SOCS1 remained unchanged. Furthermore, the induction of SOCS3
expression, under a heterologous promoter, in a radiotherapy resistant GBM cell line
increased its radiosensitivity, supporting an important implication of SOCS3 in radiotherapy
resistance acquisition. Finally, the treatment with TSA in the most radioresistant established
cell line produced an increase in the effect of radiotherapy, that correlated with an increase
in the expression of SOCS3. These effects of TSA disappeared if the increase in the expres-
sion of SOCS3 prevented with an siRNA against SOCS3. Thus, SOCS3 signal transduction
pathway (JAK/STAT) could be useful to unmask new putative targets to improve radiother-
apy response in GBM.
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Introduction
Glioblastoma multiforme (GBM) is the most common malignant tumour of the central ner-
vous system (CNS) in the adult population, its incidence being around 2–3 people per 100.000
in USA and Europe. It is considered a very aggressive and lethal tumour, because there is not
an effective therapy to date, thereby, being an incurable type of cancer [1,2].
GBM is usually divided in two groups, depending on their origin: primary GBM’s which
are developed “de novo”, and low-grade gliomas that become GBM, denominated secondary
GBM. Both are histologically identical, but primary GBM has worse prognostic than secondary
GBM [3,4].
Recently, the World Human Organization (WHO) has updated the classification of CNS
tumours, and has included molecular marks, which enable to identify the gliomas, and also
distinguish between primary and secondary GBM. This classification has established IDH-
wildtype GBM and IDH-mutant GBM; IDH-wildtype GBM has a worse prognosis, with a sur-
vival rate around 10 to 15 months, it often has mutations in the TERT promoter (76%), and
sometimes harbours alterations in TP53 (27%) and PTEN (24%). IDH-mutant GBM has a bet-
ter prognosis and the survival rate is increased to 31 months. In this type of tumours, the muta-
tions of TERT promoter are rare (26%) and TP53 and PTEN alterations are also present in a
low percentage [5].
The current therapy for GBM includes resection surgery, followed by radio and chemother-
apy, frequently given together to obtain a synergistic effect. The radiotherapy treatment con-
sists of five consecutive sessions of 2Gy at a 6Gy/min dose rate per week for six weeks, the total
treatment being 60Gy [6]. The most common drug used in chemotherapy in GBM is Temozo-
lomide (TMZ), which is administered concomitant with radiotherapy [7]. Additionally, some-
times, during resection surgery, wafers impregnated with Carmustine (BCNU) are implanted
in the environment of the tumour [8].
Despite of these aggressive treatments, the survival rate is only increased in a few months,
because GBM has different ways to acquire resistance to chemo and radiotherapy, either acti-
vating DNA repair system or producing alterations in the cell cycle and apoptosis regulation
[9,10]. Resistance to chemotherapy has been extensively studied, and it is mainly due to
MGMT (0–6 methylguanine-DNA Methyltransferase) gene expression. MGTM is a protein
involved in the DNA repair system, which is able to avoid DNA damage caused by TMZ or
BCNU [11,12]. However, there is no much knowledge about the mechanisms related to radio-
therapy resistance in GBM, and the basic mechanism of its acquisition remains unclear.
SOCS1 and SOCS3 proteins are members of the Suppressors of Cytokine Signalling (SOCS)
family. Both are implicated in the signal regulation of JAK/STAT pathway, which is involved
in cell proliferation and apoptosis [13]. Commonly, the constitutive activation of this pathway
has been considered a hallmark of several cancers [14,15]. On the other hand, SOCS proteins
alterations have been associated to different diseases, including cancer [16]. In this sense, the
methylation status of SOCS3 has been proposed as a malignant prognostic biomarker [17], and
the differential expression of SOCS1 and SOCS3 in GBM has been studied as putative factors
involved in radiotherapy resistance [18]. Likewise, the expression of these genes has been
related with radiotherapy response in other types of cancer, such as a gastric or cervix cancer
[19,20].
On the other hand, histone deacetylases inhibitors (iHDACs) have been proposed as new
anti-cancer agents [21], due to their capability to decrease the tumour progression and to
increase the radio and chemosensitivity in different tumour cell lines [22–24]. Moreover, the
iHDACS have been related to JAK-STAT pathway and SOCS1 and SOCS3 expression [25].
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In this study, six human cell lines of IDH-wildtype GBM, established from primary cultures
of GBM patients, have been obtained and characterized according to the current WHO classi-
fication. In addition, they have been tested for their chemo and radiotherapy sensitivity. The
results showed that SOCS1 and SOCS3 are overexpressed in primary GBM, and also demon-
strate a relationship between SOCS3 expression and radiotherapy resistance acquisition, sug-
gesting the utility of SOCS3 and its signal transduction pathway as a new source of therapeutic
targets.
Materials and methods
Cell culture
GBM primary cell cultures were obtained from brain aspirates of patients who have been diag-
nosed with GBM. These brain aspirates came from resection surgery of patients older than 18
years old, which had signed the informed consent. The procedures for obtaining the tissue
samples were developed in accordance with the national ethical and legal standards, and fol-
lowing the guidelines established in the Declaration of Helsinki (2000). The research project
was conducted under the written approval of the Ethic Committee of Clinical Research
(CEIC) of the “Hospital General Universitario de Elche (Spain)”, and in collaboration with the
Hospital Biobank, which are included in the Valencian Network of Biobanks.
The brain aspirates were centrifuged at 1.000 rpm, 10 min. The pellets obtained were resus-
pended in 3 volumes of Erythrocyte Lysis buffer (Qiagen), and incubated for 30 min, at 4˚C.
Then, they were again centrifuged in the same conditions, and the final pellets were resus-
pended in 10 ml of Dulbecco’s modified Eagle’s medium: Nutrient Mixture F-12 (Gibco) con-
taining 10% Fetal Bovine Serum, qualified, heat inactivated (Gibco), and 1% of streptomycin
and penicillium mixture (Biowest). This media was denominated completed DMEM F12.
These cellular suspensions were sieved using the Sieve tissue grinder kit (Sigma Aldrich). The
sieved solution was centrifuged at 1.000 rpm, 5 min. Then, it was performed an enzymatic
digestion with hyaluronidase (4.5 U/ml), and collagenase II (0.09 mg/ml) for 30 min, at 37˚C.
Finally, cellular suspensions were centrifuged at 1.000 rpm, 5 min and resuspended with com-
plete DMEM F12 media. The cell suspension was placed in a T25 flask and kept into an incu-
bator with a controlled atmosphere (37˚C, high humidity and 5% CO2). Maintenance of cell
cultures consisted in regular passes, and media replacement until they reach a growth rate sim-
ilar to cell lines.
Immunocytochemistry of GFAP, SOCS1 and SOCS3
Cells were plated in a 24 well plates at a density of 75.000 cells per well, and kept for 24 hours
into an incubator with controlled atmosphere. Then, cells were fixed with 4% paraformalde-
hyde in Dulbecco’s Phosphate-Buffered Saline (DPBS) (Gibco) during 10 min, and they were
permeabilized using 0.2% TRITON X-100 in DPBS for 10 min. In order to avoid unspecific
unions blocking was carried out with a solution of 1% Bovine Serum Albumin in DPBS for 1
hour. At that point, cells were incubated with antibodies: anti-GFAP (AB5804, Millipore),
anti-SOCS1 (ab9870, Abcam), or anti-SOCS3 (ab6030, Abcam) into a humidify chamber over-
night, at 4˚C. Primary antibodies were used to a 1/250 dilution. Next day, cells were incubated
with a secondary antibody (Molecular Probes) used to a 1/1.000 dilution, and with DAPI for 2
hours, at room temperature. In parallel, the same protocol was performed for negative con-
trols, but in this case, these cells were incubated only with the secondary antibody, without pri-
mary antibody. The immunostained cells were visualized by a Leica TCS SP2 confocal
microscope (Leica Microsystems).
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Immunocytochemistry of P53 and PTEN
Cell lines were fixed using neutral formalin and included into paraffin to build TMA (Tissue
Microarrays) sections. Then, sections were deparaffined, rehydrated and incubated with pri-
mary antibodies anti-P53 (DO-7, Dako) or anti-PTEN (6H2.1, Dako). Subsequently, the
immunocytochemistry assay was performed with streptavidin-biotin technique, using the
Immunostainer Techmate 500 (Dako), and the results were visualized by Envision System
(DakoCytomation).
Isolation of nucleic acids
DNA isolation was performed from frozen dry pellets of each cell line, using the DNAeasy
Blood & Tissue kit (Qiagen). To carry out the ARN isolation, cells were stored in RNAeasy
Lysis Buffer (Qiagen) plus 1% β-Mercaptoethanol (Sigma Aldrich), then the kit RNAeasy Plus
(Qiagen) was used to isolate RNA, according to the manufacturer’s instructions.
Western blot analysis
Protein extracts were obtained and Western blot analysis was performed following protocols
previously describe [26]. For this analysis, 100 μg of proteins per lane were resolved on 5–20%
polyacrylamide-gradient gels. SOCS3 protein was detected using a 1:500 dilution of the same
antibody used in the immunocytochemistry studies mentioned above (ab6030, Abcam).
GAPDH, was detected using a 1:5.000 dilution of a specific antibody against to this protein
(60004-1-IG. Proteintech). The secondary antibody used was a 1:10.000 dilution of a peroxi-
dase-conjugated anti-immunoglobulin (anti-IgG). For this study, three protein extracts pool
from non-tumural tissue (P1234051, BioChain; NB820-59177, Novus Biologicals; 635318,
Takara) were used as a control.
Molecular characterization of IDH1, IDH2 and TERT
The single nucleotide polymorphism of IDH1, IDH2 and TERT genes were detected by PCR,
following the protocol previously described [27,28]. In all cases, PCR was performed using 250
ng of DNA with AmpliTaq Gold 360 Master Mix (ThermoFisher Scientific). PCR products
were resolved by capillary electrophoresis in the ABI-PRISM 3500 Genetic Analyzer (Applied
Biosystem). Electropherograms were analysed by Sequencing Analysis V 5.4 Software (Applied
Biosystem).
Methylation status of MGMT
The methylation status of MGMT promotor in the cell lines was performed using SALSA
MS-MLPA ME011.B1 Mismatch Repair Genes kit (MRC-Holland) according to the protocol
provided by the manufacturer. The quantity of DNA used was 200 ng, the PCR products were
resolved in ABI-PRISM 3500 Genetic analyser (Applied Biosystem). The data from the electro-
phoretic separation were analysed using GeneScan Software (Applied Biosystems), and Micro-
soft Excel spreadsheet templates provided by the manufacture. To determine the methylation
status, the criteria proposed by Jeuken et al [29] have been used.
Expression studies
Retrotranscription of RNA to cDNA was made with 1 μg of RNA, using the High-Capacity
cDNA Reverse Transcription kit (ThermoFisher Scientific), according to the protocol pro-
vided by manufacturer.
Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
PLOS ONE | https://doi.org/10.1371/journal.pone.0212581 February 27, 2019 4 / 21
Q-PCR was carried out in 96 wells plates, with a master mix containing 1μl of specific gene
assay: MGMT (Hs01037698_M1), SOCS1 (Hs00705164_s1) or SOCS3 (Hs02330328_s1), 10 μl
TaqMan Gene Expression Master Mix (all of them from ThermoFisher Scientific) and 4 μl of
cDNA obtained by retrotranscription. Endogenous control used was GAPDH-VIC (Thermo-
Fisher Scientific). As a reference sample, an RNA pool from normal brain (temporal lobe) tis-
sue from 5 human adults was used. (BioChain). For all studies, 3 technical replicates were
performed, and negative controls were carried out with water. Q-PCR assays were performed
in the 7.300 Real Time PCR System (Applied Biosystems).
Chemo and radiotherapy
The drug used for chemotherapy was BCNU. Cells were plated, treated with 50μM BCNU for
24 hours and harvested for cellular viabilities studies.
Radiotherapy was performed in the Radiotherapy Oncology Unit of the “Hospital General
Universitario de Elche”, using a VARIANT 2100C linear accelerator. The dose was 7Gy, with a
dose rate of 6Gy/min.
For both assays, cells were plated in 6 well plates and kept into an incubator with controlled
atmosphere, for 24 hours. The radio or chemotherapy treatment was supplied, and cells were
incubated again in the same conditions for an additional period of 24 hours.
To assess the drug effect, viability studies were performed using the Muse Count & Viability
Assay Kit; radiation effect was determined by Muse Cell Cycle Assay Kit (MERK). The results
were visualized by a MUSE Cell Analyzer (MERK).
Obtain of clonal radioresistant populations
The GB39 and G242 cell lines were plated in 100 mm cell culture plates. Weekly, they were
irradiated with a 5Gy dose until reach an accumulated dose of 45Gy. Only few isolated cells
survived to this process. Each isolated cell was recovered using the Cloning cylinders glass
(Sigma Aldrich) and plated in a 96 wells plate. When these cells started to proliferate, they
were transferred to a 24 wells plate, and then to a 6 wells plates. Finally, clonal radioresistant
populations were obtained from the isolated cells.
Small interfering RNA assay
SOCS1 and SOCS3 expression inhibition was carried out by transfection with specific small
interfering RNA (siRNA). The transfection was made with specific siRNA of SOCS1 (siRNA.
SOCS1, Invitrogen) and SOCS3 (siRNA.SOCS3, Invitrogen) to a 10 μM concentration, mixed
with 5 μl of Lipofectamine RNAiMAX (Invitrogen) diluted in OPTI-MEN (Gibco). As a nega-
tive control, the same solution was used with non-specific siRNA (siRNA.NS, Invitrogen).
Transfected cells lines were maintained in this solution plus complete DMEM F12 media with-
out antibiotic for 48 hours at 37˚C in a humified 5% CO2/air atmosphere.
Upregulation of SOCS3 mRNA expression
In order to upregulated SOCS3 expression, we used a synthetic plasmid which had the SOCS3
Open Reading Frame (ORF) and a resistance cassette of Hygromycin under a heterologous
promoter provided by Sinobiological (HG11315-UT). Transfection with a control plasmid was
also performed to assess whether the transfection has an intrinsic effect. Cells were transfected
with 15 ng or 25 ng of the plasmid using Lipofectamine 2.000 (Invitrogen) diluted in OPTI--
MEN (Gibco) and grown in culture media plus Hygromycin to select only the transfected
cells. Then, the culture was divided into 3 aliquots, one for the SOCS3 expression studies, and
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the other two for cell cycle distribution studies one of them was irradiated, while the other was
not.
To induce the increase in the expression of the endogenous levels of SOCS3, the cells were
pre-treated for 16 h with different doses of TSA (25–200 nM) before proceeding to irradiation.
Statistical analysis
Mean and SD values were calculated for SOCS1 and SOCS3 expression and cell cycle distribu-
tion data. Normal distribution of the data was tested by Shapiro-Wilk test and homoscedastic-
ity was tested by Levene Test. Data from cell cycle distribution and percentages of SubG1/
G2M showed a non-normal distribution. Data from expression studies showed a normal dis-
tribution, and homogeneity of variances. Parametric and non-parametric comparation test
were used as required.
To paired comparisons between irradiated and non-irradiated phases of cell cycle, and
between the percentages of SubG1/G2M of irradiated and non-irradiated cells Mann Whitney
test was performed.
In the expression analysis, the followed criteria to consider alterations of expression were
the proposed by Schmittgen & colls [30]. They established that the alterations in expression
are significative when the RQ value is over 2, or under 0.5, corresponding to FC +/- 2 values
respectively. In the figures, the expression changes are indicated by a diamond. In order to test
the significance level of the expression changes, T- student test was performed.
P-Values <0.05 were considered to be statistically significant. The software used to carry
out the statistical analysis was SPSS 24.0 (IBM Software).
Results
Generation of six new human cell lines of GBM
Fifty-two brain aspirates were collected during this study. All of them were diagnosed as GBM
by the Anatomy Pathology Unit. The brain aspirates were processed, and primary cultures
were stablished from them. RNA, DNA and cryopreserved cells were obtained systematically
from different passages. Finally, six of these primary cultures which had a quickly and stable
growth rate and kept their molecular features, were selected for this study. The behaviour of
these six primary cultures was similar to those of a cell line. These new cell lines were named
HGUE (“Hospital General Universitario de Elche”)-GB (Glioblastoma)-number of culture, for
example: HGUE-GB-16. However, for this article they have been named GB+number of cul-
ture; for example, GB16, to facilitate easy understanding of Figures and Figures legends.
To confirm whether these six new cell lines had preserved their glial origin, immunocyto-
chemistry assays were performed to detect the expression of glial fibrillar acidic protein
(GFAP), since this protein is considered a glial marker, and particularly of astrocytes [31].
Immunolabeling analysis of these cell lines was carried out using a specific antibody anti-
GFAP, and subsequently, stained cells were visualized by confocal microscopy. All cell lines
studied showed a positive immunoreactivity against GFAP antigen (Fig 1), and it was con-
firmed that all established cell lines had preserved their glial origin.
The GMB cell lines established belonged to IDH-wildtype GBM
These new GBM cell lines were classified according to the guidelines proposed by WHO in
their 2016 CNS tumours classification [5], the “Hotspot” mutation region sequences of IDH1,
IDH2 and TERT were determined by Sanger sequencing, and the electropherograms obtained
were studied to detect the described mutations: in IDH1 R132, in IDH2 R172, and the C225T
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or C250T TERT promoter region [28,32]. No mutations of IDH1 or IDH2 were found in the
six GBM cell lines (Fig 2A, 2F, 2K, 2P, 2U, 2AA, 2B, 2G, 2L, 2Q, 2W and 2AB, respectively).
However, all of them harbour a C250T mutation in the TERT promoter (Fig 2C, 2H, 2M, 2R,
2X and 2AC). The GB16 cell line showed this mutation in heterozygosis.
P53 modifications were also analysed by immunocytochemistry, and all established GBM
cell lines had alterations in this protein, showed by P53 staining in their nuclei (Fig 2D, 2I, 2N,
2S, 2Y and 2AD). Nevertheless, the cell lines showed positive immunoreactivity to PTEN anti-
gen (Fig 2E, 2J, 2O, 2T, 2Z and 2AE), indicating that PTEN expression was conserved.
These results confirm that the established human cell lines are IDH-wildtype GBM.
Methylation status of MGMT promoter, expression of MGMT mRNA and
chemotherapy response
The methylation status of the MGMT promoter and its expression have been established as a
prognostic and response marker in GBM [33], so both features were determined in these GBM
cell lines. Methylation status was studied by MS-MLPA, and the results showed that all the cell
lines had methylated the MGMT promoter, except the GB16 cell line, which had unmethylated
all its CpG islands (S1 Fig). Furthermore, the expression of MGMT was studied by Q-PCR to
associate the methylation status with its expression level. As expected, only the GB16 cell line
showed expression of MGMT mRNA by Q-PCR, taking into consideration the MGMT pro-
moter methylation status. GB16 also exhibited overexpression of MGMT mRNA, compared to
RNA pool from non-tumoral brain tissue (Fold Change (FC) = 1.7±0.15).
Finally, we characterized the response of these GBM cell lines to BCNU, a drug used in che-
motherapy. The most chemosensitive cell line was GB42, as BCNU induced a 49.9% ± 3.7 cell
death, followed by the cell lines GB39, GB40 and GB48, which were slightly affected, their via-
bility being reduced by 25.2% ± 1.8, 19.5% ± 1.1 and 27.9% ± 2.1, respectively. The higher rate
Fig 1. Immunodetection of astrocyte marker (GFAP) in GBM cell lines. Images corresponding to immunolabeling
of GFAP (green) in GBM cell lines. Nuclei stained with DAPI are shown in blue. Each bar equals 20 μm.
https://doi.org/10.1371/journal.pone.0212581.g001
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of survival was achieved by GB16, as only the 12.6% ± 2.3 of its cells were affected by BCNU,
so it was considered a GBM resistant cell line to chemotherapy (S2 Fig).
Response to radiotherapy in primary GBM cell lines
To evaluate the radiotherapy effect, the cell lines were irradiated to a 7Gy dose (6Gy/min rate).
Then, 24 hours after treatment, the cell cycle distribution of different cells (control and
Fig 2. Molecular features of stablished GBM cell lines. Electropherograms of IDH1 (a, f, k, p, u, aa), IDH2 (b, g, l, q, w, ab), and
TERT (c, h, m, r, x, ac), and immunocytochemistry images of P53 (d, i, n, s, y, ad) and PTEN (e, j, o, t, z, ae) of all cell lines are
shown. The first line corresponds to GB16, the second line to GB37, the third line to GB39, the fourth line to GB40, the fifth line to
GB42 and the sixth line to GB48. Red rectangles show the codon which harbours the mutation. The images were made to 40.
https://doi.org/10.1371/journal.pone.0212581.g002
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irradiated) were compared to determine the response to radiotherapy. Significative changes in
the G1, S and G2/M phases were detected on each cell line due to irradiation. G1 and S phases
were reduced, and G2/M was increased, while SubG1 did not show any significant changes
(Fig 3), suggesting that the first effect of radiotherapy is to arrest cell cycle in the G2/M phase
of the cell cycle, in GBM cell lines. To determine the fate of cells blocked in phase G2/M, viabil-
ity studies were performed 72h after irradiation. The results showed an increase in the percent-
age of dead cells similar to the percentage of cells blocked in phase G2/M, 24h after irradiation,
suggesting that the initially blocked cells end up dying later on (S3 Fig).
From the data showed above, the effect of radiotherapy was calculated as the increase of
arrested cells in the G2/M phase, due to irradiation, plus the increase of cells in SubG1, since
this phase is associated to cell death (Δ (SubG1 + G2/M) IR-CTR). Any cell line reached a radio-
therapy response higher than 50%, the most affected being the GB42 cell line (49.8% ± 1.2
affected cells), and the most radioresistant being the GB39 cell line (21.2% ± 1.6 affected cells).
The rest of cell lines showed middle percentages of response.
The radiosensitivity of cell lines was also tested after grew up the cells in serum-free media,
and the value of (Δ (SubG1 + G2/M) IR-CTR) for each cell line was similar to the percentages
indicated above for the same cell line growing with 10% fetal bovine serum (S4 Fig).
Fig 3. Cell cycle distribution of GB16 (a), GB 37 (b), GB39 (c), GB40 (d), GB 42 (e) and GB48 (f). The percentage
of cells in each phase of the cell cycle is represented as the average of several experiments (mean ± SD), with the P-
value obtained from the non-parametric Mann the Whitney Test (n�10) superimposed (�� P-value< 0.01, ��� P-
value< 0.001). White bars represented control cells, and black bars irradiated cells.
https://doi.org/10.1371/journal.pone.0212581.g003
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SOCS1 and SOCS3 expression in primary GBM
To study the expression profile of SOCS1 and SOCS3 in GBM cell lines, RNA from the cell
lines in basal state (confluence level 75%, adequate quantity of nutrients and controlled atmo-
sphere) was isolated. Then, a retrotranscription and Q-PCR assay were carried out. FC values
were calculated to evaluate the expression differences between GBM and non-tumoral brain
tissue.
The GBM cell lines overexpressed SOCS1 and SOCS3, when compared to an RNA pool
from non-tumoral brain tissue. The SOCS1 expression was between 2 and 5 times higher, and
the SOCS3 expression increased in GBM cell lines between 3 and 4.5 times (S5A Fig).
Furthermore, a Western blott analysis was carried out to confirm the overexpression of
SOCS3 in the GBM cell lines. In this case, total protein extracts from the cell lines were
obtained, and then a Western blotting was performed using antibodies to SOCS3 and GAPDH
(as endogenous control). All cell lines overexpressed SOCS3 when compared to a protein pool
from non-tumoral brain tissue (S5B Fig).
Immunocytochemistry studies of SOCS1 and SOCS3 proteins
To confirm the expression data of SOCS1 and SOCS3 obtained by Q-PCR, immunocytochem-
istry assays to detect the presence of SOCS1 and SOCS3 proteins were performed in GBM cell
lines. Double immunolabeling was carried out using anti-SOCS1 and anti-SOCS3 antibodies.
The six GBM cell lines showed positive immunostaining for both proteins, which indicates
that mRNA expression was correlated with protein presence. SOCS1 and SOCS3 proteins
appeared in the cytoplasm, without apparently association to any organelle and no presence in
the nuclei. The double immunolabeling did not show colocalization of these proteins in the
cytoplasm (Fig 4).
Effect of the radiotherapy exposure on the SOCS1 and SOCS3 expression at
mRNA level
In order to study the effect of radiotherapy on SOCS1 and SOCS3 mRNA expression, GBM cell
lines were exposed to 7Gy, and 24 hours after irradiation cells were harvested, and total RNA
was isolated. In parallel, control non-irradiated cells were collected to be used as an expression
control. No significant changes were observed in SOCS1 and SOCS3 mRNA levels after irradia-
tion (Fig 5A).
To determine whether SOCS1 and SOCS3 mRNA expression was significative affected after
exposure to radiotherapy, time-course and dose-response experiments were performed. In this
case, the study was carried out in the most radioresistant cell line (GB39), and in the most
radiosensitive one (GB42). Non-treated cell lines were used as expression control, and RQ val-
ues were calculated from them. Changes in SOCS1 and SOCS3 mRNA expression were not
detected in GB39 nor GB42 at different times (Fig 5B). Moreover, changes on SOCS1 and
SOCS3 expression were undetected in dose-response experiments (Fig 5C), with the only
exception of the GB39 cell line, where its expression was reduced by half, in comparison with
the control (RQ = 0.5 ±0.03) at the highest radiotherapy dose.
Reduction of SOCS1 and SOCS3 mRNA expression by small interfering
RNA (siRNA) and its effect on radiotherapy resistance
To determine whether SOCS1 and/or SOCS3 play a role in GBM radioresistance, SOCS1 and
SOCS3 expression was inhibited using siRNA. First, we studied that transfection with non-spe-
cific siRNA (siRNA.NS) did not altered SOCS1 and SOC3 expression, nor cell cycle
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distribution. The results did not show significative differences between control and siRNA.NS
transfected cells in any cases (S6 Fig).
Subsequently, parallel assays of expression pre-irradiation and cell cycle post-irradiation
were carried out. In this case, we compared the mRNA expression between siRNA.NS trans-
fected cells and siRNA.SOCS1 or siRNA.SOCS3 transfected cells, which demonstrated that
expression of SOCS1 and SOCS3 was significative reduced. Cell cycle distribution was also
studied in each sample (siRNA.NS, siSOCS1, siSOCS3) in order to evaluate the effect of radio-
therapy (Fig 6).
The mRNA expression of SOCS1 was reduced by 70% in siRNA.SOCS1 transfected cells
when compared to siRNA.NS (Fig 6A). However, the effect of irradiation was the same on
siRNA.NS and siRNA.SOCS1 cells (Fig 6B and 6C). Therefore, the radiotherapy response was
not affected by SOCS1 expression reduction.
The expression of SOCS3 was reduced by 73% in siRNA.SOCS3 transfected cells (Fig 6D).
Furthermore, the irradiation caused a significative differential effect in siRNA.NS and siRNA.
SOCS3 transfected cells (Pvalue < 0.001). The siRNA.SOCS3 transfected cells were more
radioresistant than the cells transfected with siRNA.NS, since their percentage of cells in the
SubG1 and G2/M phases post-irradiation was smaller than the number of cells in these phases
in the siRNA.NS transfected cells (Fig 6E and 6F). These data reveal that SOCS3 expression
inhibition provides resistance to radiotherapy in GBM cell lines.
Fig 4. Immunolocalization of SOCS1 and SOCS1 in GBM cell lines. Images show immunolabeling of SOCS1 (red)
and SOCS3 (green) of GBM cell lines: GB16 (a, b, c), GB37 (d, e, f), GB39 (g, h, i), GB40 (j, k, l), GB42 (m, n, o), GB48
(p, q, r). Nuclei stained with DAPI are shown in blue. Each bar equals 20 μm.
https://doi.org/10.1371/journal.pone.0212581.g004
Fig 5. Expression of SOCS1 and SOCS3 after radiotherapy in GBM cell lines. Values of RQ ± SD 24 hours post-irradiation of SOCS1 and SOCS3 in
all cell lines (a), and values of RQ ± SD obtained by time course (b) and dose-response (c) studies in GB 39 and in GB42. Black bars correspond to
SOCS1 RQ values, and white bars to SOCS3 RQ values. ^ means changes in expression. � Indicate a P-value< 0.05 (n�3).
https://doi.org/10.1371/journal.pone.0212581.g005
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SOCS1 and SOCS3 mRNA expression in clonal radioresistant populations
Clonal radioresistant populations were obtained from the most radioresistant cell line (GB39),
and from the most radiosensitive cell line (GB42). After an accumulated 45Gy (5Gy/week)
dose treatment, 10 clonal survival populations were isolated from GB39, and 6 from GB42.
Finally, 6 clonal survival populations from GB39, and 1 from GB42 were obtained.
As expected, cell cycle analysis showed that the isolated clonal populations were more
radioresistant than their parental cell line (Fig 7A and 7D). The expression of SOCS1 and
SOCS3 at mRNA level was determined in all of them. While the expression of SOCS1 was
unmodified (Fig 7B and 7E), the expression of SOCS3 was significantly lower in all clonal
Fig 6. SOCS1 and SOCS3 interfering assay and its biological effect on radiotherapy response. Mean ± SD of relative
mRNA expression of SOCS1 (a) and SOCS3 (d) in siRNA.NS, siRNA.SOCS1 and siRNA.SOCS3 transfected cells.
Mean Percentage of arrested cells in SubG1 and G2/M phases due to radiotherapy in siRNA.NS and siRNA.SOCS1 (b),
and in siRNA.NS and siRNA.SOCS3 (e). Representation of 95% confidence interval of radiotherapy response in
siRNA.NS and siRNA.SOCS1 (c), and in siRNA.NS and siRNA.SOCS3 transfected cells (f). ^ means changes in
expression. ��� Indicate P-value<0.001 (n�3).
https://doi.org/10.1371/journal.pone.0212581.g006
Fig 7. Cell cycle analysis, and SOCS1 and SOCS3 expression on the clonal isolated resistant populations and parental cell lines. Data are
presented as the mean percentage ± SD of arrested cells in SubG1 and G2/M phase due to radiotherapy. arrested (a,d). Mean ± SD of SOCS1 mRNA
expression (b, e) and SOCS3 (c, f) in parental cell lines and clonal populations. ^ means changes in expression. � Indicate P-value<0.05, �� Indicate
P-value<0.01, and ��� indicate P-value<0.001 (n�3).
https://doi.org/10.1371/journal.pone.0212581.g007
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radioresistant populations in contrast to their parental cell lines (Fig 7C and 7D). These results
reinforce the data obtained by siRNA.
Induction of SOCS3 expression and its role in the radiotherapy response
Induction of SOCS3 expression by a heterologous promoter. The study of radiotherapy
sensitization was performed in the most radioresistant GBM cell line (GB39). In order to
achieve the upregulating of SOCS3, this cell line was transfected with 15 ng or 25 ng of syn-
thetic plasmid, which contains the SOCS3 ORF under a heterologous promoter control.
The increase of SOCS3 mRNA expression was evaluated by Q-PCR, and the data obtained
confirmed that cells transfected with 15ng and 25 ng of SOCS3 plasmid increased the expres-
sion of SOCS3, when compared to cells transfected with control plasmid. The cells transfected
with 25 ng of plasmid showed four times increase in SOCS3 mRNA level, and the cells trans-
fected with 15 ng showed three times increase (Fig 8A), which suggest that the amount of plas-
mid correlates with the increase of gene expression.
In relation to the radiotherapy effect, cells with higher SOCS3 mRNA expression showed a
greater response to irradiation, compared to control cells. The percentage of cells in SubG1
and G2/M phases was twice as much in cells transfected with SOCS3 plasmid than in cells
transfected with control plasmid (Fig 8B). Therefore, when SOCS3 is upregulating the culture
showed a better response to radiotherapy.
Induction of endogenous SOCS3 expression by TSA treatment. Finally, we wondered
whether increasing endogenous SOCS3 expression by an alternative treatment, such as the
iHDAC named TSA, will be able to sensitize the most radioresistant established cell line to
radiotherapy. To test this hypothesis, the cells were pre-treated for 16 hours with different
doses of TSA, in a range from 25–200 nM. Then, the expression of SOCS3 mRNA was deter-
mined just before the irradiation, and the effect of radiotherapy was determined 24 hours after
the treatment by cell cycle analysis. The SOCS3 mRNA expression was increased by TSA treat-
ment in a dose-depended manner (Fig 9A), and the radiosensitive of GB39 cell line also
increased in the same way (Fig 9B).
To demonstrate that the TSA-induced increase in radiosensitivity showed in the radioresis-
tant cell line was due to the increase in SOCS3 expression, a siRNA experiment blocking
SOCS3 expression was performed, with or without TSA pre-treatment, keeping on this way
the SOCS3 mRNA levels downregulated. In these conditions, the radiosensitization effects of
TSA disappeared (Fig 9C and 9D).
Fig 8. Induction of SOCS3 expression by a heterologous promoter. Mean ± SD values of relative expression of
SOCS3 (a) and cellular mean percentages of cells in SubG1 and G2/M phases (b). CTR: sample transfected with control
plasmid, 15ng and 25ng: cells transfected with 15 and 25 ng of SOCS3 synthetic plasmid, respectively. ^ means changes
in expression. �� Indicate P-value<0.01 (n�3).
https://doi.org/10.1371/journal.pone.0212581.g008
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The effect of TSA was also tested in the most radiosensitivity cell line (GB42) following the
same conditions used for GB39. In this case, the endogenous levels of SOCS3 and the percent-
ages of SubG1+G2/M remained unchanged for all TSA concentrations tested (S7 Fig).
Discussion
The progression of GBM is fast and difficult to control, due to its chemo and radioresistance.
Hence, it is very important to obtain accurate models to study this type of cancer. For that pur-
pose, there are many cell lines which mimic GBM, such as U87MG or LN229 (ATCC collec-
tion), but these cell lines are far away from the patient state and they usually have been
modified to achieve an immortalized status. The six new human GBM cell lines established in
this study resemble more the patient state, because not only they were originated from them
but also, they preserve their glial nature and molecular features of the initial tumour and they
lack any artificially induced modification. Other advantage of using these cell lines from pri-
mary cultures is the possibility to recreate their progression and go back and forth in their
development to study gene expression or physiological properties, as DNA, RNA and cryopre-
served cells have been stored at different passages.
The molecular studies of these cell lines have confirmed that they were included in the
IDH-wildtype GBM, which is the most aggressive GBM group, according to 2016 WHO SNC
classification. Moreover, they harbour TERT mutations in their promoters, and alterations in
P53, two characteristics that support the fact that they are indeed primary GBM [5]. To date,
the only IDH-wildtype GBM well characterized according to WHO are these cell lines, so they
Fig 9. TSA pre-treatment and its effect upon cell cycle and SOCS3 expression. White bars show mean ± SD of
SOCS3 mRNA expression in the different experiments (a,c). Striped bars represent mean percentages ± SD of cells in
SubG1 and G2/M phases (b,d). ^ means changes in expression
�� Indicate P-value<0.01, ��� Indicate P-value<0.001
(n�3).
https://doi.org/10.1371/journal.pone.0212581.g009
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can be used as a proper model of primary GBM to study the malignant features of these
tumours.
In relation to chemotherapy, all these cell lines showed a middle response to BCNU treat-
ment, reinforcing their classification as primary GBM. The most resistant cell line affected
only by 12.6% ± 2.3, was GB16. Epigenetic results indicated that this cell line has the MGMT
promoter methylated, and unlike the rest of cell lines, it expresses this gene at the mRNA level.
Furthermore, we demonstrated the relationship between MGMT promoter methylation status
and chemoresistance, which has been postulated in many previous studies [33]. However, the
low response obtained by the other cell lines suggest that resistance to alkylating drugs must be
regulated by other mechanisms not confirmed as yet, such as the presence of tumour stem
cells, capable of resisting treatment and replace dead cells, already described in other types of
cancers[34,35].
Moreover, radiotherapy affected the distribution of the cells in the different phases of the
cell cycle, reducing the cellular percentage in the G1 and S phases, and increasing the percent-
age of cells in G2/M phase. Thus, the statistically significant increase of arrested cells in the G2/
M phase was stablished as a hallmark to determine the radiotherapy effect on these cell lines.
According to this value, the GBM cell lines showed a low radiotherapy response, and never
reached more than 50%, indicating again that they belong to the worst prognostic group.
SOCS genes have been associated with carcinogenesis and tumour progression [36]. Partic-
ularly, SOCS1 and SOCS3 have been postulated as candidates to regulate the radio and che-
moresistance acquisition in other types of cancer, such as prostate cancer [37,38], or cervix
cancer[20], but there is a lack of studies regarding the role of SOCS1 and SOCS3 in radiother-
apy resistance in GBM. These genes inhibit the cytokine response in many cell types, including
CNS, and are involved in the immune response [39]. SOCS proteins also modulate the JAK--
STAT pathway, which is involved in many cellular processes, such as cell migration, cell prolif-
eration and apoptosis. SOCS1 and SOCS3 have three different ways to inhibit the JAK/STAT
pathway: first, they can bind directly to JAKs proteins, silencing their activity; second, SOCS
can bind and block STAT proteins; and finally, they can establish connections with the BC
complex and Cullin 5, promoting JAK ubiquitination [14].
SOCS1 and SOCS3 were overexpressed in the six GBM cell lines analysed. This increase in
mRNA expression has been previously reported in breast cancer where SOCS family plays a
role in tumour proliferation [40]. The expression of these genes remained constant after differ-
ent doses and radiotherapy periods, yet there are no studies in GBM and other cancers related
to expression changes of these genes due to radiotherapy. However, a similar study in sarcoma
has identified several genes implicated in chemoresistance [41]. Therefore, it is relevant to per-
form these studies to dilucidate the expression changes involved in radioresistance. On the
other hand, the inhibition of SOCS1 expression by a siRNA did no change the radiotherapy
response in any of the six cell lines, and the isolated clonal resistant populations did not show
any modification in the level of SOCS1 mRNA expression, indicating that SOCS1 is not directly
related to radioresistance acquisition in GBM, as it was postulated by Zhou et al [18]. The rea-
son for the discrepancy is unknown, but their studies were carried out only in a GBM cell line
(U87) and SOCS1 was ectopically expressed, because it was silenced in U87 cells by promoter
methylation [18]. Meanwhile, our data have been obtained in six different new established cell
lines where the SOCS1 promoter is not methylated. In contrast, the inhibition of SOCS3
expression by siRNA significantly increased radioresistance of the six cell lines studied, and
also there was a downregulation of SOCS3 mRNA levels in all the isolated clonal radioresistant
populations, suggesting again that SOCS3 plays a key role in GBM radioresistance. Zhou et al
indicated that the depletion of SOCS3 induced radiosensitivy, though in their study SOCS3
wasn’t directly silenced, and radiotherapy response was tested only in U87 cell line which
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expressed a phosphorylation-deficient DN STAT3 allele [18], and this mutation could affect
the whole JAK-STAT pathway. Moreover, our results about SOCS3 are in agreement with pre-
vious studies that have hypothesised the relationship between the methylation of the SOCS3
promoter and poor prognosis in GBM [17], and its low expression and worse response in
other cancers [19,20]. Furthermore, low levels of SOCS3 could lead to an increase in the JAK/
STAT pathway activation, which would contribute to acquisition of features of tumour inva-
sion and metastasis [15].
To further support the implication of SOCS3 in radioresistance acquisition, SOCS3 expres-
sion was induced under a heterologous promoter in the most radioresistant established cell
line (GB39). Upregulation of SOCS3 produced radiosensitization in this cell line demonstrat-
ing again, that SOCS3 participates in GBM radioresistance. Finally, the endogenous expression
of SOCS3 was also upregulated by TSA treatment, and again the most radioresistant cell line
showed an increase in its radiosensitivity, in a TSA dose-depended way. This effect of TSA dis-
appeared when the increase in SOCS3 expression induced by TSA was blocked by SOCS3.
siRNA. Previous studies in myeloproliferative neoplasms and colorectal cancer, indicated that
TSA treatment increases the SOCS3 expression, and this increase repressed the cell growth in
both type of cancers [25,42]. These publications also reveal the increase of SOCS3 expression
was associated to a lower activation of JAK/STAT pathway, reinforcing the key role of SOCS3
and JAK/STAT pathway in radioresistance acquisition proposed in this work.
The data obtained in this study demonstrate the implication of SOCS3 expression in radio-
therapy resistance acquisition in GBM, so the downregulation of SOCS3 expression by siRNA
increased the radiotherapy resistance in all the cell lines tested. In the same sense, a statistically
significant downregulation of SOCS3 mRNA was observed in all the isolated radioresistant
clonal population, when compared with the parental cell line. On the other hand, the induc-
tion of SOCS3 expression under a heterologous promoter in the most resistant established cell
line induced its radiosensitization. Finally, the pre-treatment with TSA in the stablished cell
lines produced an increase in SOCS3 expression levels and a parallel radiosensitization of these
cells. Interestingly, the effects of TSA are completely abrogated when the increase in SOCS3
mRNA produced by this drug is blocked by SOCS3 siRNA.
Taken together, the results probe that SOCS3 plays a key role in radioresistance acquisition
in GBM, and reveal the possible implication of the JAK/STAT pathway, which is inhibited by
SOCS, in response to radiotherapy. These findings show that SOCS3 and its signal transduc-
tion pathway could be considered as a source of putative new targets to overcome GBM
radioresistance.
Supporting information
S1 Fig. Methylation status of MGMT promoter of GBM cell lines: GB16 (a), GB37 (b),
GB39 (c), GB 40 (d), GB42 (e), GB 48 (f). Black bars show control methylated CpG islands.
Yellow lines show the threshold to consider a methylated CpG island, following the Jeuken
et al [29] criteria. Red arrows, on different colours bars, indicate the CpG islands of MGMT. In
the abscissa axis, all promoter of genes studied by SALSA MS-MLPA ME011.B1 Mismatch
Repair Genes kit are shown.
(TIF)
S2 Fig. BCNU effect. Bars show the percentage ± SD of cell death in each cell line.
(TIF)
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S3 Fig. Radiotherapy effect 72 hours post-treatment. Bars show the percentage ± SD of cell
death in each cell line.
(TIF)
S4 Fig. Radiotherapy effect in cell lines grown in serum-free media. Bars show the effect of
radiotherapy as the (Δ (SubG1 + G2/M) IR-CTR) ± SD.
(TIF)
S5 Fig. (a) Expression profile of SOCS1 and SOCS3 in primary GBM cell lines. Fold change
(FC) values ± SD of SOCS1 mRNA expression (black bars), and SOCS3 mRNA expression
(white bars) are shown for each cell line represented in the X-axis. (b): Western blot analysis of
SOCS3 expression on total protein extracts from established cell lines. The molecular sizes of
the bands are shown to the right.
(TIF)
S6 Fig. Analysis of siRNA transfection effect by itself. Representation of the 95% confidence
interval of % of cells in the SubG1 and G2/M phases (a) and mRNA expression (b) for control
(CTR) and transfected with non-specific siRNA (siRNA.NS) cells.
(TIF)
S7 Fig. TSA pre-treatment and its effect upon cell cycle and SOCS3 expression. White bars
show mean ± SD of SOCS3 mRNA expression in the different experiments (a). Striped bars
represent mean percentages ± SD of cells in SubG1 and G2/M phases (b). (n�3).
(TIF)
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